Aura Biosciences (AURA) grants stock options and RSUs to its CMO

Rhea-AI Filing Summary

Aura Biosciences reported that Chief Medical Officer Janet Jill Hopkins received new equity awards. She was granted a stock option for 160,944 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.

She also acquired 89,056 shares of common stock at $0.00 per share through a restricted stock unit award, bringing her directly held common stock to 321,340 shares after the transaction. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service.

The option vests with 25% of the underlying shares vesting on February 1, 2027, and the remaining 75% vesting pro rata in 36 monthly installments, also subject to her continued service on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkins Janet Jill

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		89,056(1)	A	$0	321,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	03/02/2026		A		160,944		(2)	03/02/2036	Common Stock	160,944	$0	160,944	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Conor Kilroy, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Aura Biosciences (AURA) report for Janet Jill Hopkins?

Aura Biosciences reported equity awards to Chief Medical Officer Janet Jill Hopkins. She received a stock option for 160,944 shares and 89,056 restricted stock units at $0.00 per share, both classified as grant or award acquisitions under the company’s 2021 Stock Option and Incentive Plan.

How many Aura Biosciences (AURA) shares does Janet Jill Hopkins own after this Form 4?

After these awards, Janet Jill Hopkins directly holds 321,340 Aura Biosciences common shares. This total reflects the addition of 89,056 shares granted via restricted stock units at no cash cost, on top of her previously reported directly held common stock position.

What are the vesting terms of Janet Jill Hopkins’ restricted stock units at Aura Biosciences (AURA)?

The restricted stock units vest over four years. The 89,056 RSUs convert into common shares in four substantially equal annual installments starting January 15, 2027, provided Hopkins continues to serve the company on each scheduled vesting date under the 2021 Stock Option and Incentive Plan.

How do the new stock options for Aura Biosciences (AURA) Chief Medical Officer vest?

The 160,944-share stock option vests in stages. Twenty-five percent of the option vests on February 1, 2027, with the remaining 75% vesting pro rata in 36 monthly installments, all conditioned on Hopkins’ continued service at each vesting date.

Did Janet Jill Hopkins buy or sell Aura Biosciences (AURA) shares on the open market?

No open-market buy or sell is reported. The Form 4 shows grant or award acquisitions at $0.00 per share: a stock option and restricted stock units, both issued as part of compensation rather than through market purchases or sales of Aura Biosciences stock.

What plan governs Janet Jill Hopkins’ new Aura Biosciences (AURA) equity awards?

Both awards are issued under Aura’s 2021 Stock Option and Incentive Plan. The RSUs each represent the right to receive one common share, and the stock option provides the right to buy 160,944 shares, all subject to the plan’s terms and vesting conditions.